Prestige Brands同意收购GSK的北美非核心OTC品牌

Pharmadeals Review Pub Date : 2012-06-01 DOI:10.3833/pdr.v2012i1.1646

Heather Cartwright

{"title":"Prestige Brands同意收购GSK的北美非核心OTC品牌","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i1.1646","DOIUrl":null,"url":null,"abstract":"In order to focus on its priority brands and emerging markets, GlaxoSmithKline (GSK) has agreed to divest 17 of its non-core consumer brands in the US and Canada to Prestige Brands for £426 M (US$661 M) in cash. The sale of the OTC brands will generate net proceeds of approximately £242 M (US$375 M), which will be returned to GSK’s shareholders during 2012. The transaction is expected to complete in the first half of 2012, subject to regulatory approvals.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"64 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i1.1646\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to focus on its priority brands and emerging markets, GlaxoSmithKline (GSK) has agreed to divest 17 of its non-core consumer brands in the US and Canada to Prestige Brands for £426 M (US$661 M) in cash. The sale of the OTC brands will generate net proceeds of approximately £242 M (US$375 M), which will be returned to GSK’s shareholders during 2012. The transaction is expected to complete in the first half of 2012, subject to regulatory approvals.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"64 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i1.1646\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i1.1646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

为了专注于其优先品牌和新兴市场，葛兰素史克(GSK)已同意以4.26亿英镑(6.61亿美元)现金将其在美国和加拿大的17个非核心消费品牌出售给Prestige brands。OTC品牌的出售将产生约2.42亿英镑(3.75亿美元)的净收益，这些收益将在2012年返还给GSK的股东。该交易预计将于2012年上半年完成，但需获得监管部门的批准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands

In order to focus on its priority brands and emerging markets, GlaxoSmithKline (GSK) has agreed to divest 17 of its non-core consumer brands in the US and Canada to Prestige Brands for £426 M (US$661 M) in cash. The sale of the OTC brands will generate net proceeds of approximately £242 M (US$375 M), which will be returned to GSK’s shareholders during 2012. The transaction is expected to complete in the first half of 2012, subject to regulatory approvals.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量